Clinical and demographic characteristics of the patient population include in the analysis (n = 167)
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group* . | Group (1) vs (4)† . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| Age at diagnosis, y | |||||||
| < 45 | 8 (10) | 1 (5) | 2 (7) | 5 (15) | 16 (10) | ||
| 45-54 | 28 (34) | 10 (48) | 12 (41) | 8 (23) | 58 (35) | ||
| 55-64 | 47 (57) | 10 (48) | 15 (52) | 21 (62) | 93 (56) | ||
| Median | 56 y | 55 y | 55 y | 56 y | 56 y | .59‡ | .46§ |
| Charlson comorbidity score | |||||||
| 0 | 67 (81) | 18 (86) | 22 (76) | 26 (76) | 133 (80) | ||
| 1 | 12 (14) | 1 (5) | 3 (10) | 7 (21) | 23 (14) | ||
| 2+ | 4 (5) | 2 (9) | 4 (14) | 1 (3) | 11 (7) | .39‖ | .66‖ |
| Stage | |||||||
| I/II | 2 (2) | 0 (0) | 3 (10) | 1 (3) | 6 (4) | ||
| III/IV | 81 (98) | 21 (100) | 26 (90) | 33 (97) | 161 (96) | .22‖ | 1.00‖ |
| B symptoms at presentation | |||||||
| No | 65 (78) | 11 (52) | 21 (72) | 24 (71) | 121 (72) | ||
| Yes | 18 (22) | 10 (48) | 8 (28) | 10 (29) | 46 (27) | .13‖ | .47‖ |
| IPI risk group | |||||||
| L | 15 (18) | 8 (38) | 6 (21) | 11 (32) | 40 (24) | ||
| LI | 40 (48) | 7 (33) | 14 (48) | 18 (53) | 79 (47) | ||
| HI | 20 (24) | 5 (24) | 8 (28) | 5 (15) | 38 (23) | ||
| H | 8 (10) | 1 (5) | 1 (3) | 0 (0) | 10 (6) | .30‖ | .08‖ |
| Median follow-up, mo | 33 | 24 | 36 | 33 | 33 | .63‡ | .95‡ |
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group* . | Group (1) vs (4)† . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| Age at diagnosis, y | |||||||
| < 45 | 8 (10) | 1 (5) | 2 (7) | 5 (15) | 16 (10) | ||
| 45-54 | 28 (34) | 10 (48) | 12 (41) | 8 (23) | 58 (35) | ||
| 55-64 | 47 (57) | 10 (48) | 15 (52) | 21 (62) | 93 (56) | ||
| Median | 56 y | 55 y | 55 y | 56 y | 56 y | .59‡ | .46§ |
| Charlson comorbidity score | |||||||
| 0 | 67 (81) | 18 (86) | 22 (76) | 26 (76) | 133 (80) | ||
| 1 | 12 (14) | 1 (5) | 3 (10) | 7 (21) | 23 (14) | ||
| 2+ | 4 (5) | 2 (9) | 4 (14) | 1 (3) | 11 (7) | .39‖ | .66‖ |
| Stage | |||||||
| I/II | 2 (2) | 0 (0) | 3 (10) | 1 (3) | 6 (4) | ||
| III/IV | 81 (98) | 21 (100) | 26 (90) | 33 (97) | 161 (96) | .22‖ | 1.00‖ |
| B symptoms at presentation | |||||||
| No | 65 (78) | 11 (52) | 21 (72) | 24 (71) | 121 (72) | ||
| Yes | 18 (22) | 10 (48) | 8 (28) | 10 (29) | 46 (27) | .13‖ | .47‖ |
| IPI risk group | |||||||
| L | 15 (18) | 8 (38) | 6 (21) | 11 (32) | 40 (24) | ||
| LI | 40 (48) | 7 (33) | 14 (48) | 18 (53) | 79 (47) | ||
| HI | 20 (24) | 5 (24) | 8 (28) | 5 (15) | 38 (23) | ||
| H | 8 (10) | 1 (5) | 1 (3) | 0 (0) | 10 (6) | .30‖ | .08‖ |
| Median follow-up, mo | 33 | 24 | 36 | 33 | 33 | .63‡ | .95‡ |
RHCVAD indicates rituximab fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone; HDT, high-dose therapy; ASCR, autologous stem cell rescue; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; and IPI, International Prognostic Index.
“P value 4-group” refers to the statistical significance across all four therapy groups.
“Group (1) vs (4)” refers to the P value of the association between patients in the RHCVAD and RCHOP + HDT/ASCR therapy groups.
Kruskal-Wallis test.
Mann-Whitney U test.
Fisher exact test.